Single-dose rituximab therapy for refractory idiopathic membranous nephropathy: A single-center experience

Takayuki Katsuno, Takenori Ozaki, Hangsoo Kim, Noritoshi Kato, Yasuhiro Suzuki, Shinichi Akiyama, Takuji Ishimoto, Tomoki Kosugi, Naotake Tsuboi, Yasuhiko Ito, Shoichi Maruyama

研究成果: Article

4 引用 (Scopus)

抜粋

To date, a recognized treatment for refractory membranous nephropathy (MN) has not been established. Recently, several reports have indicated the efficacy of rituximab as a novel treatment option. However, only a few published accounts exist of rituximab therapy for idiopathic MN (IMN) in the Asian population. We present the cases of three IMN patients who were treated with single-dose rituximab after they showed no response to conventional therapies, including corticosteroids, cyclosporine, cyclophosphamide, mizoribine, and mycophenolate mofetil. Although one case showed no response, a complete or incomplete remission was achieved in the other two cases. Rituximab may therefore be a beneficial treatment option for IMN.

元の言語English
ページ(範囲)1679-1686
ページ数8
ジャーナルInternal Medicine
56
発行部数13
DOI
出版物ステータスPublished - 2017

All Science Journal Classification (ASJC) codes

  • Internal Medicine

フィンガープリント Single-dose rituximab therapy for refractory idiopathic membranous nephropathy: A single-center experience' の研究トピックを掘り下げます。これらはともに一意のフィンガープリントを構成します。

  • これを引用

    Katsuno, T., Ozaki, T., Kim, H., Kato, N., Suzuki, Y., Akiyama, S., Ishimoto, T., Kosugi, T., Tsuboi, N., Ito, Y., & Maruyama, S. (2017). Single-dose rituximab therapy for refractory idiopathic membranous nephropathy: A single-center experience. Internal Medicine, 56(13), 1679-1686. https://doi.org/10.2169/internalmedicine.56.7908